How Risk
Is Sold.

"This pill cuts your risk by 50%."

It's on the news, in the leaflet, in the conversation across the desk. Halves your risk. Cuts it by a third. Reduces it by 25%. It sounds enormous — and it's designed to. Who would say no to halving their risk of a heart attack?

But there's a question almost nobody is taught to ask, and it changes everything. It's not whether the number is true — usually it is. It's which number they're telling you. Because there are two, and they can describe the exact same pill while sounding worlds apart.

Relative, and absolute.

Say that, without any pill, 2 people in 100 like you would have a heart attack over the next ten years. A pill comes along that brings it down to 1 in 100.

• The relative number: it went from 2 to 1 — that's a 50% reduction. True. And it's the number you'll be told.
• The absolute number: it went from 2% to 1% — a difference of 1 person in 100. Also true. And it's the number you'll almost never hear.

Same pill. Same study. "Cuts your risk in half" and "helps 1 person in 100" are the identical fact, described two ways. One sounds like a miracle. The other sounds like what it is.

The headline always picks the number that sounds bigger.

It never changes. That's the point.

Here's the quiet genius of the relative number: it stays the same no matter how small your real risk is. A pill that "cuts risk by 25%" earns that headline whether your risk was 40 in 100 or 2 in 100 — whether it saves 10 people or half of one.

So the relative number can make a treatment sound powerful for everyone, while hiding the fact that for a low-risk person, the actual benefit is close to nothing. The absolute number would give the game away — so the absolute number is the one that goes unmentioned.

This cuts both ways.

This isn't a reason to wave away every drug — and that matters, because a tool that only ever says "no" isn't a thinking tool, it's a prejudice. Drag the slider back up to the high end and watch: for someone whose real risk is genuinely high, that same "25%" becomes a large, real benefit — several whole people in a hundred, saved.

So the tool doesn't tell you drugs are good or bad. It tells you to find out which person you are before you decide — because the benefit lives entirely in your own baseline risk, and that's the one thing the headline hides.

Once you have it, it's everywhere.

This single tool reappears behind an enormous amount of what you'll be told about your health — statins and cholesterol, cancer screening, blood-pressure pills, hormone therapy, daily aspirin, the newest supplement. Every one of them can be sold with a relative number that sounds dramatic and hides a modest absolute one — or, for the right person, a genuinely large one.

It's why this is a thinking tool rather than a piece about one disease. The other pieces here — on sugar, on diabetes, and the ones to come — will each hit a moment where a risk number is doing the persuading. When they do, they'll point back here. Because once you can ask "from what, to what?", you can read the whole landscape for yourself.